Table 3 Comparison of clinical outcome when data from different regimens of luteal triptorelin were cumulated
From: GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial
No Triptorelin | < 35 years | BP | PR | DR | IR | AR |
|---|---|---|---|---|---|---|
87/279 (31,2%) | 72/279 (25,8%) | 66/279 (23,6%) | 17,52% | 24,1% | ||
Triptorelin | < 35 years | 168/507 (33,1%) | 153/507 (30,1%)* | 143/507 (28,2%)* | 23,45%* | 14,8% |
No Triptorelin | ≥ 35 years | 71/241 (29,4%) | 61/241 (25,3%) | 54/241 (22,4%) | 14,12% | 23,9% |
Triptorelin | ≥ 35 years | 104/317 (32,8%) | 93/317 (29,3%)* | 87/317 (27,4%)* | 19,78%* | 16,3% |
No Triptorelin | Total patients | 158/520 (30,3%) | 133/520 (25,6%) | 120/520 (23,1%) | 15,6% | 24,05% |
Triptorelin | Total patients | 272/824 (33%) | 246/824 (29,8%)** | 230/824 (27,9%)** | 22,15%** | 15,4% |